drugset / Trial / NCT02285439
Study of MEK162 for Children With Low-Grade Gliomas
Phase 1/2
Completed
105 enrolled
Children's Hospital Los Angeles
Dana-Farber Cancer Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to study the drug MEK162 in children with a brain tumor call low-grade glioma, as well as in children with other tumors in which a specific growth signal is abnormally turned on. The main questions it aims to answer are: What is the correct dose of MEK162 in children? What are the side effects of MEK162 in children? Is MEK162 effective in children with low-grade glioma? Participants on the study receive MEK162 by mouth twice daily for up to 2 years.
Timeline
- Start
- 2016-05-04
- Primary completion
- 2022-11-02
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | 15 mg | Oral |